COSCIENS Biopharma released its earnings results on Nov 11, 2025. The company reported -$0.572 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.572.

Is COSCIENS Biopharma overvalued?

According to Wall Street analysts COSCIENS Biopharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does COSCIENS Biopharma pay dividends?

COSCIENS Biopharma does not currently pay dividends.

What is COSCIENS Biopharma’s EPS estimate?

COSCIENS Biopharma’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does COSCIENS Biopharma have?

COSCIENS Biopharma has 3,182,963 shares outstanding.

What happened to COSCIENS Biopharma’s price movement after its last earnings report?

COSCIENS Biopharma reported an EPS of -$0.572 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.122%.

Which hedge fund is a major shareholder of COSCIENS Biopharma?

Currently, no hedge funds are holding shares in CSCIF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

COSCIENS Biopharma

COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.